المؤلفون: M. Mandrina O., V. Breder V., M. Ivanov V., A. Lebedeva A., V. Gorbatsevich V., K. Laktionov K., P. Kononets V., М. Мандрина О., В. Бредер В., М. Иванов В., А. Лебедева А., В. Горбацевич В., К. Лактионов К., П. Кононец В.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2021); 154-159 ; Медицинский Совет; № 9 (2021); 154-159 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: MET mutation, PD-L1, immunotherapy, NSCLC, crizotinib, мутация MET, иммунотерапия, немелкоклеточный рак легкого, кризотиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6267/5681; König D., Savic Prince S., Rothschild S.I. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel). 2021;13(4):804. https://doi.org/10.3390/cancers13040804.; Socinski M.A., Pennell N.A., Davies K.D. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021;5:653–663. https://doi.org/10.1200/PO.20.00516.; Sierra J.R., Tsao M.S. c-MET as a Potential Therapeutic Target and Biomarker in Cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21–S35. https://doi.org/10.1177/1758834011422557.; Awad M.M., Oxnard G.R., Jackman D.M., Savukoski D.O, Hall D., Shivdasanietal P. et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016;34(7):721–730. https://doi.org/10.1200/JCO.2015.63.4600.; Titmarsh H.F., O’Connor R., Dhaliwal K., Akram A.R. The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy. Front Oncol. 2020;10:54. https://doi.org/10.3389/fonc.2020.00054.; Sabari J.K., Montecalvo J., Chen R., Dienstag J.A., Mrad C., Bergagnini I. et al. PD-L1 Expression and Response to Immunotherapy in Patients with MET Exon 14-Altered Non-Small Cell Lung Cancers (NSCLC). J Clin Oncol. 2017;35(15_ suppl):8512–8512. https://doi.org/10.1200/JCO.2017.35.15_suppl.8512.; Xing X., Guo J., Ding G., Li B., Dong B., Feng Q. et al. Analysis of PD1, PDL1, PDL2 Expression and T Cells Infiltration in 1014 Gastric Cancer Patients. Oncoimmunology. 2017;7(3):e1356144. https://doi.org/10.1080/2162402x.2017.1356144.; Glodde N., Bald T., van den Boorn-Konijnenberg D., Nakamura K., O’Donnell J.S., Szczepanski S. et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789.e9–802.e9. https://doi.org/10.1016/j.immuni.2017.09.012.; Papaccio F., Della Corte C.M., Viscardi G., Di Liello R., Esposito G., Sparano F. et al. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. Int J Mol Sci. 2018;19(11):3595. https://doi.org/10.3390/ijms19113595.; Salgia R., Sattler M., Scheele J., Stroh C., Felip E. The Promise of Selective MET Inhibitors in Non-Small Cell Lung Cancer with MET Exon 14 Skipping. Cancer Treat Rev. 2020;87:102022. https://doi.org/10.1016/j.ctrv.2020.102022.; Liang H., Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis. Onco Targets Ther. 2020;13:2491–2510. https://doi.org/10.2147/OTT.S231257.; Garajová I., Giovannetti E., Biasco G., Peters G.J. c-Met as a Target for Personalized Therapy. Transl Oncogenomics. 2015;7(Suppl 1):13–31. https://doi.org/10.4137/TOG.S30534.; Baltschukat S., Engstler B.S., Huang A., Hao H.X., Tam A., Wang H.Q. et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019;25(10):3164–3175. https://doi.org/10.1158/1078-0432.ccr-18-2814.; Klempner S.J., Borghei A., Hakimian B., Ali S.M., Ou S.I. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. J Thorac Oncol. 2017;12(1):152–156. https://doi.org/10.1016/j.jtho.2016.09.127.; Wang S.X.Y., Zhang B.M., Wakelee H.A., Koontz M.Z., Pan M., Diehn M. et al. Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small-Cell Lung Cancers with Response to Crizotinib and Cabozantinib. Anticancer Drugs. 2019;30(5):537–541. https://doi.org/10.1097/CAD.0000000000000765.; Waqar S.N., Morgensztern D., Sehn J. MET Mutation Associated with Responsiveness to Crizotinib. J Thorac Oncol. 2015;10(5):e29–e31. https://doi.org/10.1097/JTO.0000000000000478.; https://www.med-sovet.pro/jour/article/view/6267

الاتاحة: https://www.med-sovet.pro/jour/article/view/6267
https://doi.org/10.21518/2079-701X-2021-9-154-159

المؤلفون: N. Mitiushkina V., I. Stepanov A., D. Yurlov O., E. Filippova A., S. Odintsova V., A. Lozhkina M., S. Orlov V., A. Iyevleva G., Н. Митюшкина В., И. Степанов А., Д. Юрлов О., Е. Филиппова А., С. Одинцова В., А. Ложкина М., С. Орлов В., А. Иевлева Г.

المساهمون: This work was supported by the grant of the Russian Science Foundation № 19-15-00312., Работа поддержана грантом Российского научного фонда № 19-15-00312.

المصدر: Siberian journal of oncology; Том 19, № 4 (2020); 132-137 ; Сибирский онкологический журнал; Том 19, № 4 (2020); 132-137 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-4

مصطلحات موضوعية: lung cancer, ALK translocation, crizotinib, ceritinib, alectinib, рак легкого, транслокации ALK, кризотиниб, церитиниб, алектиниб

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1539/777; Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S,. Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature. 2007 Aug 2; 448(7153): 561–6. doi:10.1038/nature05945.; Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14; 131(6): 1190–203. doi:10.1016/j.cell.2007.11.025.; Hsu K.H., Ho C.C., Hsia T.C., Tseng J.S., Su K.Y., Wu M.F., Chiu K.L., Yang T.Y., Chen K.C., Ooi H., Wu T.C., Chen H.J., Chen H.Y., Chang C.S., Hsu C.P., Hsia J.Y., Chuang C.Y., Lin C.H., Chen J.J., Chen K.Y., Liao W.Y., Shih J.Y., Yu S.L., Yu C.J., Yang P.C., Chang G.C. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLoS One. 2015 Mar 19; 10(3): e0120852. doi:10.1371/journal.pone.0120852.; Kris M.G., Johnson B.E., Berry L.D., Kwiatkowski D.J., Iafrate A.J., Wistuba I.I., Varella-Garcia M., Franklin W.A., Aronson S.L., Su P.F., Shyr Y., Camidge D.R., Sequist L.V., Glisson B.S., Khuri F.R., Garon E.B., Pao W., Rudin C., Schiller J., Haura E.B., Socinski M., Shirai K., Chen H., Giaccone G., Ladanyi M., Kugler K., Minna J.D., Bunn P.A. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19): 1998–2006. doi:10.1001/jama.2014.3741.; Barlesi F., Mazieres J., Merlio J.P., Debieuvre D., Mosser J., Lena H., Ouafik L., Besse B., Rouquette I., Westeel V., Escande F., Monnet I., Lemoine A., Veillon R., Blons H., Audigier-Valette C., Bringuier P.P., Lamy R., Beau-Faller M., Pujol J.L., Sabourin J.C., Penault-Llorca F., Denis M.G., Lantuejoul S., Morin F., Tran Q., Missy P., Langlais A., Milleron B., Cadranel J., Soria J.C., Zalcman G.; Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 2; 387(10026): 1415–1426. doi:10.1016/S0140-6736(16)00004-0.; Gervas P., Ivanova A., Vasiliev N., Ananina O., Cheremisina O., Popova N., Goldberg V., Choynzonov E., Cherdyntseva N., Zharkova O., Rogovieva O., Verzhbitskaya N., Didichuk I., Cherdyntsev E. Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia. Asian Pac J Cancer Prev. 2015; 16(2): 689–692. doi:10.7314/APJCP.2015.16.2.689.; Christensen J.G., Zou H.Y., Arango M.E., Li Q., Lee J.H., McDonnell S.R., Yamazaki S., Alton G.R., Mroczkowski B., Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Mol Cancer Ther. 2007 Dec; 6(12 Pt 1): 3314–22. doi:10.1158/1535-7163.MCT-07-0365.; Zou H.Y., Li Q., Lee J.H., Arango M.E., McDonnell S.R., Yamazaki S., Koudriakova T.B., Alton G., Cui J.J., Kung P.P,. Nambu M.D., Los G., Bender S.L., Mroczkowski B., Christensen J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1; 67(9): 4408–17. doi:10.1158/0008-5472.CAN-06-4443.; Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., Riely G.J., Solomon B., Ou S.H., Kim D.W., Salgia R., Fidias P., Engelman J.A., Gandhi L., Jänne P.A., Costa D.B., Shapiro G.I., Lorusso P., Ruffner K., Stephenson P., Tang Y., Wilner K., Clark J.W., Shaw A.T. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10): 1011–9. doi:10.1016/S1470-2045(12)70344-3.; Sahu A., Prabhash K., Noronha V., Joshi A., Desai S. Crizotinib: A comprehensive review. South Asian J Cancer. 2013 Apr; 2(2): 91–7. doi:10.4103/2278-330X.110506.; Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., Thomas M., O'Byrne K.J., Moro-Sibilot D., Camidge D.R., Mok T., Hirsh V., Riely G.J., Iyer S., Tassell V., Polli A., Wilner K.D., Jänne P.A. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385–94. doi:10.1056/NEJMoa1214886.; Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., Iyer S., Reisman A., Wilner K.D., Tursi J., Blackhall F.; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23): 2167–77. doi:10.1056/NEJMoa1408440.; Arbour K.C., Riely G.J. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017; 31(1): 101–11. doi:10.1016/j.hoc.2016.08.012.; Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010 Jul; 46(10): 1773–80. doi:10.1016/j.ejca.2010.04.002.; Morán T., Quiroga V., Gil Mde L., Vilà L., Pardo N., Carcereny E., Capdevila L., Muñoz-Mármol A.M., Rosell R. Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013; 2(2): 128–41. doi:10.3978/j.issn.2218-6751.2013.03.04.; Lindeman N.I., Cagle P.T., Beasley M.B, Chitale D.A., Dacic S., Giaccone G., Jenkins R.B., Kwiatkowski D.J., Saldivar J.S., Squire J., Thunnissen E., Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013 Jul; 8(7): 823–59. doi:10.1097/JTO.0b013e318290868f.; Conde E., Taniere P., Lopez-Rios F. The anaplastic lymphoma kinase testing conundrum. Expert Rev Mol Diagn. 2015 Feb; 15(2): 161–3. doi:10.1586/14737159.2015.997713.; Richards M.W., Law E.W., Rennalls L.P., Busacca S., O'Regan L., Fry A.M., Fennell D.A., Bayliss R. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proc Natl Acad Sci USA. 2014; 111(14): 5195–200. doi:10.1073/pnas.1322892111.; Richards M.W., O'Regan L., Roth D., Montgomery J.M., Straube A., Fry A.M., Bayliss R. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain. Biochem J. 2015; 467(3): 529–36. doi:10.1042/BJ20150039.; Bayliss R., Choi J., Fennell D.A., Fry A.M., Richards M.W. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci. 2016; 73(6): 1209–24. doi:10.1007/s00018-015-2117-6.; Sabir S.R., Yeoh S., Jackson G., Bayliss R. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel). 2017; 9(9): E118. doi:10.3390/cancers9090118.; Woo C.G., Seo S., Kim S.W., Jang S.J., Park K.S., Song J.Y., Lee B., Richards M.W., Bayliss R., Lee D.H., Choi J. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol. 2017; 28(4): 791–7. doi:10.1093/annonc/mdw693.; Noh K.W., Lee M.S., Lee S.E., Song J.Y., Shin H.T., Kim Y.J., Oh D.Y., Jung K., Sung M., Kim M., An S., Han J., Shim Y.M., Zo J.I., Kim J., Park W.Y., Lee S.H., Choi Y.L. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. J Pathol. 2017; 243(3): 307–19. doi:10.1002/path.4950.; Heuckmann J.M., Balke-Want H., Malchers F., Peifer M., Sos M.L., Koker M., Meder L., Lovly C.M., Heukamp L.C., Pao W., Küppers R., Thomas R.K. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012; 18(17): 4682–90. doi:10.1158/1078-0432.CCR-11-3260.; Murakami Y., Mitsudomi T., Yatabe Y. A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol. 2012 Mar 16; 2: 24. doi:10.3389/fonc.2012.00024.; Yoshida T., Oya Y., Tanaka K., Shimizu J., Horio Y., Kuroda H., Sakao Y., Hida T., Yatabe Y. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct; 34(28): 3383–9. doi:10.1200/JCO.2015.65.8732.; Li Y., Zhang T., Zhang J., Li W., Yuan P., Xing P., Zhang Z., Chuai S., Li J., Ying J. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer. 2018; 118: 128–133. doi:10.1016/j.lungcan.2018.01.026.; Lei Y.Y., Yang J.J., Zhang X.C., Zhong W.Z., Zhou Q., Tu H.Y., Tian H.X., Guo W.B., Yang L.L., Yan H.H., Chen H.J., Xie Z., Su J., Han J.F., Wu Y.L. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clin Lung Cancer. 2016 May; 17(3): 223–31. doi:10.1016/j.cllc.2015.09.002.; Cha Y.J., Kim H.R., Shim H.S. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J Transl Med. 2016; 14(1): 296. doi:10.1186/s12967-016-1061-z.; McLeer-Florin A., Duruisseaux M., Pinsolle J., Dubourd S., Mondet J., Phillips Houlbracq M., Magnat N., Fauré J., Chatagnon A., de Fraipont F., Giaj Levra M., Toffart A.C., Ferretti G., Hainaut P., Brambilla E., Moro-Sibilot D., Lantuejoul S. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018; 116: 15–24. doi:10.1016/j.lungcan.2017.12.004.; Lin J.J., Zhu V.W., Yoda S., Yeap B.Y., Schrock A.B., Dagogo-Jack I., Jessop N.A., Jiang G.Y., Le L.P., Gowen K., Stephens P.J., Ross J.S., Ali S.M., Miller V.A., Johnson M.L., Lovly C.M., Hata A.N., Gainor J.F., Iafrate A.J., Shaw A.T., Ou S.I. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018; 36(12): 1199–1206. doi:10.1200/JCO.2017.76.2294; Christopoulos P., Endris V., Bozorgmehr F., Elsayed M., Kirchner M., Ristau J., Buchhalter I., Penzel R., Herth F.J., Heussel C.P., Eichhorn M., Muley T., Meister M., Fischer J.R., Rieken S., Warth A., Bischoff H., Schirmacher P., Stenzinger A., Thomas M. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer. Int J Cancer. 2018; 142(12): 2589–2598. doi:10.1002/ijc.31275.; Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N., Ivantsov A.O., Togo A.V., Polyakov I.S., Orlov S.V., Matsko D.E., Novik V.I., Imyanitov E.N. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013; 121(7): 370–6. doi:10.1002/cncy.21281.; Iyevleva A.G., Raskin G.A., Tiurin V.I., Sokolenko A.P., Mitiushkina N.V., Aleksakhina S.N., Garifullina A.R., Strelkova T.N., Merkulov V.O., Ivantsov A.O., Kuligina E.Sh., Pozharisski K.M., Togo A.V., Imyanitov E.N. Novel ALK fusion partners in lung cancer. Cancer Lett. 2015; 362(1): 116–21. doi:10.1016/j.canlet.2015.03.028.; Mitiushkina N.V., Tiurin V.I., Iyevleva A.G., Kholmatov M.M., Filippova E.A., Moiseyenko F.V., Levchenko N.E., Sardaryan I.S., Odintsova S.V., Lozhkina A.M., Volkov N.M., Karaseva N.A., Moiseyenko V.M., Orlov S.V., Imyanitov E.N. Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants. Biochimie. 2018 Nov; 154: 19–24. doi:10.1016/j.biochi.2018.07.018.; Reguart N., Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. Future Oncol. 2015; 11(8): 1245–57. doi:10.2217/fon.15.15.; https://www.siboncoj.ru/jour/article/view/1539

الاتاحة: https://www.siboncoj.ru/jour/article/view/1539
https://doi.org/10.21294/1814-4861-2020-19-4-132-137

المؤلفون: E. Reutova V., L. Laktionova V., D. Marinov T., D. Peregudov A., T. Borisova N., Е. Реутова В., Л. Лактионова В., Д. Маринов Т., Д. Перегудов А., Т. Борисова Н.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 176-181 ; Медицинский Совет; № 9 (2020); 176-181 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ALK translocation, non-small cell lung cancer, targeted therapy, crizotinib, транслокация ALK, немелкоклеточный рак легкого, таргетная терапия, кризотинибтранслокация ALK, кризотиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5721/5219; Sahu A., Prabhash K., Noronha V., Joshi A., Desai S. Crizotinib: A comprehensive review. South Asian J Cancer. 2013;2(2):91–97. doi:10.4103/2278-330X.110506.; Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T. et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa1408440.; Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.-J. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886. Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Моисеенко Ф.В., Реутова Е.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2019;9(3s2):32–48. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf. Laktionov K.K., Artamonova E.V., Breder V.V., Gorbunova V.A., Moiseenko F.V., Reutova E.V. et al. Practical guidelines for the medicinal treatment of non-small cell cancer. Zlokachestvennye opukholi = Malignant Tumours. 2019;9(3s2):2–48. (In Russ.) Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf.; Demidova I., Grinevich V., Avdalian A., Imyanitov E., Gikalo М., Savelov et al. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches Lung Cancer. 2017;103:17–23. 10.1016/j.lungcan.2016.11.001.; Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. SOJ Thoracic Oncology. 2009;4(12):1450–1454. doi:10.1097/JTO.0b013e3181c4dedb.; Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945.; Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi:10.1200/JCO.2009.22.6993.; Демидова И.А., Цепенщикова Е.О., Баринов А.А., Гагарин И.М., Савелов Н.А., Гриневич В.Н., Тюляндин С.А. Определение перестроек гена ALK в селектированной популяции российских больных немелкоклеточным раком легкого. Злокачественные опухоли. 2013;3(7):3–9. doi:10.18027/2224-5057-2013-3-3-9. Demidova I.A., Tepenshchikova E.O., Barinov А.А., Gagarin I.M., Savelov N.A., Grinevich V.N., Tulyandin S.A. Determination of ALK gene rearrangements in a selected population of Russian patients with non-small cell lung cancer. Zlokachestvennye opukholi = Malignant Tumours. 2013;3(7):3–9. (In Russ.) doi:10.18027/2224-5057-2013-3-3-9.; Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B. et al. Activity and safety of crizotinib in patients with ALK-positive non-smallcell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. doi:10.1016/S1470-2045(12)70344-3.; Blackhall F., Ross Camidge D., Shaw A.T., Soria J.C., Solomon B.J., Mok T. et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219. doi:10.1136/esmoopen-2017-000219.; Shaw A.T., Kim T.M., Crinò L., Gridelli C., Kiura K., Liu G. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886. doi:10.1016/S1470-2045(17)30339-X.; Novello S., Mazières J., Oh I.J., de Castro J., Migliorino M. R., Helland Å. et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416. doi:10.1093/annonc/mdy121.; Huber R.M., Hansen K.H., Paz-Ares Rodriguez L., West H.L., Reckamp K.L., Leighl N.B. et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2020;15(3):404–415. doi:10.1016/j.jtho.2019.11.004.; Solomon B.J., Besse B., Bauer T.M., Felip E., Soo R.A., Camidge D.R. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654– 1667. doi:10.1016/S1470-2045(18)30649-1.; Rangachari D., Le X., Shea M., Huberman M. S., Van der Laan P.A., Kobayashi S.S., Costa D.B. Cases of ALK-Rearranged Lung Cancer with 5-Year ProgressionFree Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017;12(11):e175-e177. doi:10.1016/j.jtho.2017.06.002.; Solomon B.J., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E. et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794.; Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L. et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903– 21917. doi:10.18632/oncotarget.15746.; Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838. doi:10.1056/NEJMoa1704795.; Sakakibara-Konishi J., Kitai H., Ikezawa Y., Hatanaka Y., Sasaki T., Yoshida R. et al. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. Clinical Lung Cancer. 2019;20(5):e555-e559. doi:10.1016/j.cllc.2019.06.021.; Shaw A.T., Friboulet L., Leshchiner I., Gainor J.F., Bergqvist S., Brooun A. et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54–61. doi:10.1056/NEJMoa1508887.; https://www.med-sovet.pro/jour/article/view/5721

الاتاحة: https://www.med-sovet.pro/jour/article/view/5721
https://doi.org/10.21518/2079-701X-2020-9-176-181

المؤلفون: S. Bagrova G., A. Kolomeytseva A., E. Trusilova V., V. Gorbunova A., С. Багрова Г., А. Коломейцева А., Е. Трусилова В., В. Горбунова А.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 120-124 ; Медицинский Совет; № 19 (2019); 120-124 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: non-small cell lung cancer, ALK translocation, alectinib, crizotinib, немелкоклеточный рак легкого, транслокация ALK, кризотиниб, алектиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5278/4808; Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394. doi:10.1056/NEJMoa1214886.; Tsao A.S., Scagliotti G.V., Bunn P.A. Jr, Carbone D.P., Warren G.W., Bai C., et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613-638. DOI:10.1016/j.jtho.2016.03.012.; Novello S., Mazieres J., Oh I.J., de Castro J., Migliorino M.R., Helland A., et al. Primary Results from the Phase III ALUR Study of Alectinib versus Chemotherapy in Previously Treated ALK+Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology 2017;28(suppl_5):v605-v649. doi:10.1093/annonc/mdx440.058.; Kerr K.M., López-Ríos F. Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol. 2016;27(Suppl 3):iii16-iii24. doi:10.1093/annonc/mdw302.; Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440.; Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L., Descourt R., Dansin E., Audigier-Valette C., Moreau L., et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive nonsmall-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903-21917. doi:10.18632/oncotarget.15746.; Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-SmallCell Lung Cancer. N Engl J Med. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795.; Shaw A.T., Gandhi L., Gadgeel S., Riely G. et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234-242. doi:10.1016/S1470-2045(15)00488-X.; Ou S.H., Ahn J.S., De Petris L., Govindan R., Yang J.C., Hughes B., Lena H., Moro-Sibilot D., Bearz A., Ramirez S.V., et al. Alectinib in crizotinib-refractory ALK- rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-668. doi:10.1200/JCO.2015.63.9443.; Gadgeel S.M., Ganghi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C. et al. Safety and activity of alectenib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer: results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119-1128. doi:10.1016/S1470-2045(14)70362-6.; Реутова Е.В., Лактионов К.К. Новые возможности в лечении больных ALK-позитивным немелкоклеточным раком легкого. Онкология. Журнал им. П.А. Герцена. 2019;8(3):226-230. doi:10.17116/onkolog2019803115226.; Mok T.S.K., Shaw A.T., Camidge R.D., Gadgeel S.M., Rosell R., Dziadziuszko R., et al. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Annals of Oncology. 2019;30(Suppl_5):mdz260.006. doi:10.1093/annonc/mdz260.006.; https://www.med-sovet.pro/jour/article/view/5278

الاتاحة: https://www.med-sovet.pro/jour/article/view/5278
https://doi.org/10.21518/2079-701X-2019-19-120-124

المؤلفون: Бредер, В., Лактионов, К., Юдин, Денис, Хамрина, Н.

مصطلحات موضوعية: НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО, ТРАНСЛОКАЦИЯ ГЕНА ALK, ALK-ПОЗИТИВНЫЙ РАК ЛЕГКОГО, КРИЗОТИНИБ, ЦЕРИТИНИБ, АЛЕКТИНИБ, РЕЗИСТЕНТНОСТЬ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/terapiya-alk-pozitivnogo-nemelkokletochnogo-raka-legkogo-realnost-i-perspektivy
http://cyberleninka.ru/article_covers/15795815.png

المؤلفون: Ovsiannikova, D.I.

المصدر: Practical oncology; Том 2, № 4 (2019); 50-56
Практическая онкология-Praktična onkologìâ; Том 2, № 4 (2019); 50-56
Практична онкологія-Praktična onkologìâ; Том 2, № 4 (2019); 50-56

مصطلحات موضوعية: ALK-положительный немелкоклеточный рак легкого, ингибитор тирозинкиназы, ALK-ингибиторы, таргетные препараты, алектиниб, кризотиниб, ALK-позитивний недрібноклітинний рак легені, інгібітор тирозинкінази, ALK-інгібітори, таргетні препарати, алектиніб, кризотиніб, ALK-positive non-small-cell lung cancer, Tyr-kinase inhibitors, ALK inhibitors, target agents, alectinib, crizotinib

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::f0438a5d23022ff990b2e802cd71adf7
http://oncology.zaslavsky.com.ua/article/view/195187

المصدر: Российский онкологический журнал.

مصطلحات موضوعية: НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО, ТРАНСЛОКАЦИЯ ГЕНА ALK, ALK-ПОЗИТИВНЫЙ РАК ЛЕГКОГО, КРИЗОТИНИБ, ЦЕРИТИНИБ, АЛЕКТИНИБ, РЕЗИСТЕНТНОСТЬ

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::cda3d151bd49cc3c168f449e2d2d53a9
http://cyberleninka.ru/article/n/terapiya-alk-pozitivnogo-nemelkokletochnogo-raka-legkogo-realnost-i-perspektivy